Nickolls Sarah A, Fleck Beth, Hoare Sam R J, Maki Rich A
Neurocrine Biosciences Inc, Sandwich, Kent, UK.
J Pharmacol Exp Ther. 2005 Jun;313(3):1281-8. doi: 10.1124/jpet.105.083337. Epub 2005 Mar 2.
Agonists of the melanocortin 4 (MC4) receptor have potential pharmaceutical benefit in the treatment of obesity and sexual dysfunction. In this study, we have compared the ability of a number of peptide and nonpeptide agonists to activate a FLAG-tagged human MC4 (FMC4) receptor, as measured by both cAMP accumulation and calcium mobilization using a fluorometric imaging plate reader (FLIPR). In addition, we have analyzed the ability of these agonists to cause receptor internalization, as measured by fluorescence-activated cell sorting analysis. The endogenous agonist alpha-melanocortin-stimulating hormone (alpha-MSH) increased cAMP accumulation, calcium mobilization, and receptor internalization in a dose-dependent manner in human embryonic kidney 293 cells expressing the FMC4 receptor. The activity of the other agonists varied considerably in these assays, and overall, the potency and intrinsic activity of the agonists in the cAMP accumulation assays did not correlate with their potency or intrinsic activity in either the FLIPR or receptor internalization assays. Agonists could be clearly separated into two functional classes based on their structure. Peptide agonists beta-MSH, des-acetyl-alpha-MSH, and [Nle(4), D-Phe(7)]-alpha-melanocortin-stimulating hormone exhibited 80 to 112% of the maximal alpha-MSH response in cAMP accumulation and 62 to 96% in FLIPR assays and were able to cause 75 to 118% of receptor internalization induced by alpha-MSH. Conversely, although the nonpeptide agonists exhibited 73 to 149% of the alpha-MSH response in the cAMP accumulation assays, they were significantly impaired in the FLIPR (7-40%) and receptor internalization (-5-38%) assays. These findings demonstrate an important difference in activation and internalization of the MC4 receptor by nonpeptide versus peptide agonists and provides evidence of agonist-specific conformational states.
黑皮质素4(MC4)受体激动剂在治疗肥胖症和性功能障碍方面具有潜在的药用价值。在本研究中,我们比较了多种肽类和非肽类激动剂激活带有FLAG标签的人MC4(FMC4)受体的能力,通过使用荧光成像板读数仪(FLIPR)检测环磷酸腺苷(cAMP)积累和钙动员来进行衡量。此外,我们还分析了这些激动剂引起受体内化的能力,通过荧光激活细胞分选分析来进行测定。内源性激动剂α-促黑素细胞激素(α-MSH)在表达FMC4受体的人胚肾293细胞中,以剂量依赖的方式增加cAMP积累、钙动员和受体内化。在这些检测中,其他激动剂的活性差异很大,总体而言,激动剂在cAMP积累检测中的效力和内在活性与它们在FLIPR或受体内化检测中的效力或内在活性不相关。基于其结构,激动剂可明显分为两个功能类别。肽类激动剂β-MSH、去乙酰-α-MSH和[Nle(4), D-Phe(7)]-α-促黑素细胞激素在cAMP积累检测中表现出α-MSH最大反应的80%至112%,在FLIPR检测中表现出62%至96%,并且能够引起α-MSH诱导的75%至118%的受体内化。相反,尽管非肽类激动剂在cAMP积累检测中表现出α-MSH反应的73%至149%,但它们在FLIPR检测(7%至40%)和受体内化检测(-5%至38%)中明显受损。这些发现证明了非肽类与肽类激动剂在激活和内化MC4受体方面存在重要差异,并提供了激动剂特异性构象状态的证据。